0001213900-26-098844.txt : 20260910 0001213900-26-098844.hdr.sgml : 20260910 20260910170004 ACCESSION NUMBER: 0001213900-26-098844 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260910 DATE AS OF CHANGE: 20260910 EFFECTIVENESS DATE: 20260910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd. CENTRAL INDEX KEY: 0001536196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-597072 FILM NUMBER: 261371840 BUSINESS ADDRESS: STREET 1: 26 BEN GURION STREET CITY: RAMAT GAN STATE: L3 ZIP: 5257346 BUSINESS PHONE: 972 39241114 MAIL ADDRESS: STREET 1: 26 BEN GURION STREET CITY: RAMAT GAN STATE: L3 ZIP: 5257346 D 1 primary_doc.xml X0708 D LIVE 0001536196 Can-Fite BioPharma Ltd. 26 BEN GURION STREET RAMAT GAN L3 ISRAEL 5257346 +972 (3) 924-1114 ISRAEL None None Corporation true Motti Farbstein c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Executive Officer Chief Executive Officer, Chief Financial Officer and Chief Operating Officer Pnina Fishman c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Executive Officer Executive Chairman of the Board and Chief Scientific Officer Sari Fishman c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Executive Officer Vice President of Business Development Guy Regev c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Director Abraham Sartani c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Director Yoseph Bornstein c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Director Ilan Tamir c/o Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan L3 ISRAEL 5257346 Director Pharmaceuticals Decline to Disclose 06b false 2026-09-02 false true true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor NEW YORK NY NEW YORK 10022 TX TEXAS false 8306884 8306884 0 Form D covers wts issued 9/3/26: investor wts (3,183,476 @ $2.50/share) and PA wts (111,422 at $3.125/share). Excludes exercise of warrants issued March 2026. Total offering amount equals exercise price of new wts if exercised in full. false 1 278554 0 7% cash fee + 1% mgmt. fee to HCW on warrant exercise proceeds. In addition, $25,000 for non-accountable expenses and $50,000 for accountable expenses. HCW agent warrants included in Item 13. 0 Issuer expects to use any proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.. No proceeds are expected to be paid to executive officers, directors, or promoters. false Can-Fite BioPharma Ltd. /s/ Motti Farbstein Motti Farbstein Chief Executive Officer 2026-09-10